THOMSON REUTERS INTEGRITYSM DISCOVER THE UNDISCOVERED Jenna OH Solution Consultnat, Life Science

OBJECTIVES By the end of this module you will be able to: • State key strengths of Thomson Reuters Integrity which differentiate it from other “pipeline” databases  Identify the contents provided in Integrity

 Understand the unique features of Integrity  Address benefits you can get from Integrity

2

AGENDA • Introduction of Integrity • Contents of Integrity • Benefit of yours by using Integrity • Live Demo

3

LS solutions for the Pharmaceutical Industry

Cortellis for Competitive Intelligence  BD/Licensing

Cortellis for Clinical Trials Intelligence

4

Life Sciences Decision Support from Thomson Reuters Disease Biology

Drug R&D

Drug Pipeline

Regulatory

Thomson Reuters MetaCore

Thomson Reuters Integrity

Thomson Reuters Pharma & Newport

IDRAC

Biological pathway and target discovery

Cross-disciplinary content

Integrated business and science content

Regulatory decision support

• Manually curated biological pathway maps • Chemistry, genomics, biomarkers & pathology data • Target discovery and drug repositioning

• Drugs pipeline and patent content for early stage research • Biology, chemistry and pharmacology data • Biomarkers module linking drugs, targets and genes to biomarkers

• Drug pipeline, deals, sales forecasts, select patent & scientific information • Generic drug Intelligence • Current awareness and competitive intelligence • Market information, patent expiry, API manufacturers

• Regulatory environment in 70 global markets • Value add explanatory documents and regulatory Intelligence

• Understand disease and enrich your pathway insight • Identify upstream and downstream effects • Integrate proprietary data with public knowledge

• Understand disease, select drug targets • Demonstrate safety and efficacy • Design experiments

• Evaluate market opportunities and competitors’ pipelines • Source / evaluate licensing and acquisition deals • identify / evaluate generic drug opportunities

• Design global regulatory submission / drug approval strategies

What is Integrity?

JOINING THE DOTS: UNDERSTANDING THE MOLECULAR BASIS OF DISEASE USING MANUAL CURATION

9045 Publications with “BRCA1” & “Cancer” in title/abstract*

9886 Publications with “BRCA1” in title/abstract*

BRCA1 ~1 hour per paper = 377 days without sleep/rest!

~1 hour per paper = 412 days without sleep/rest!

*Searches performed 8th of Aug 2013 in Pubmed

THOMSON REUTERS INTEGRITY – INTEGRATED SCIENTIFIC INTELLIGENCE • Thomson Reuters Integrity is a scientifically-focused drug R&D

database that accelerates early stage drug research. • Integrity enables organizations to make better informed decisions earlier in the research process regarding: – which projects to start or stop; – which drug targets to work on; and – which lead compounds to prioritize.

8

INTEGRITY AND CORTELLIS FOR CI Integrity

Cortellis for CI

• More Scientific details

• More Commercial details

• Info to help identify and validate biological targets and lead compounds

• Info to help identify and validate companies as M&A or partnership candidates

• Stronger in Preclinical stages/Disease & target demonstration

• Stronger in Clinical stages and post launch

9

INTEGRITY AND METACORE Metacore

Integrity

• Provides molecular understanding of disease

• Provides pharmaceutical pipeline competitor intelligence for the scientific researchers

• Analyze and undersand experimental findings (Omics data) in the context of validated biological pathway • Generate hypotheses around novel targets, biomarkers, mechanisms of action

• Prioritize research activities with evaluation of prior art and competitors • Validate hypotheses with biomarker, drug, chemistry, pharmacology and PK content

10

What benefits come to you?

CRITICAL BUSINESS ISSUES AT THIS EARLY STAGE? What should we work on next?

Is our compound novel?

Do we have freedom to operate?

Have we missed something?

Do we have all the facts to back up our decision?

Is our compound better than the competition?

12

INTEGRITY’S KEY STRENGTHS • Integrated biological, chemical and pharmacological data to provide insights and support decision-making. • A focus on Scientific Intelligence, including detailed pharmacokinetic (PK) and pharmacology data points for benchmarking experimental performance of compounds. • Extensive coverage of Early Stage Research to ensure you don’t miss any important competitive compounds Biology

Pharmacology

Chemistry

13

Benefits from using Integrity • Enhance your productivity  With Integrity you can find in minutes what might take several days with other resources. This frees up time for core research activities, planning and analysis

• Make more informed decisions with greater confidence  The information in Integrity is carefully refined from multiple sources and cross-correlated by our experts. As a result you can get an overview of the current drug or target landscape, and stay on top of important developments with minimal effect.

• Benchmark the performance of your compounds  To guide prioritization decisions- quickly identify in vitro, in vivo and human points, and details of the assays used to see how you compare to the competition.

14

What contents are provided?

Managing Information Budgets Multiple Data Sources Patent offices – WO (PCTs), EP, JP, US, CN, IN, KR Biomedical literature – >15,000 journals Congresses, symposia, meetings – > 400/year Company information – > 6063 organizations Regulatory information Scientific websites Clinical Trial Registries Press Releases

Access to 13 Knowledge Areas Drugs & Biologics Targets Genomics Organic Synthesis Experimental Pharmacology Experimental Models Biomarkers*

Pharmacokinetics / Metabolism Clinical Studies Disease Briefings Companies & Research Institutions Literature Patents

Maximizing Resources A team of over 80 indexers manually index data, saving your organization the cost of staffing, managing this effort and the risk of missing something crucial with an adhoc effort. 16

INTEGRATED SCIENTIFIC INTELLIGENCE

Biology

Targets; Genomics; Biomarkers.

Disease Briefings

Clinical Studies

Drugs and Biologics Pharmacology; Animal Models; Pharmacokinetics.

Pharmacology

Chemistry

Structures; Organic Synthesis

17

Integrity Contents Growth 2013 Knowledge Area

Counts as of July

Drugs & Biologics

404,572

Targets & Pathways

2,268

Genomics

24,825

Biomarkers

22,006

Organic Synthesis & Intermediates

25,159

Experimental Pharmacology

1,344,915

Experimental Models

11,448

Pharmacokinetics/metabolism

559,497

Clinical Studies

202,190

Disease Briefings

141

Company & Research Institutions

10,156

Literature

1,615,398

Patents

226,655 18

EXAMPLE: Searching paclitaxel in Integrity You can find the detail info of paclitaxel in terms of related biomrker, experimental pharmacology, experimental model, disease briefing, etc. as the below.

19

EXAMPLE: Drugs & Biologics

20

EXAMPLE: Statistic analysis

21

Experimental Pharmacology

22

EXAMPLE: Target& Pathway Search

23

EXAMPLE: Target& Pathway Search

24

EXAMPLE: Experimental model • You can see which experimental model has been used for the condition of interest. • You can check what is the best model for the condition of your interest. able to be filtered by

EXAMPLE: Synthetic routes • You can see how it is able to be synthesized. • You can check what approach has been explored.

26

Biomarker Modules: Add-on

Paradigm Change

In-depth of understanding on pathogenesis/mechanism of disease

Biomarkers reliably predict the patients of target: Companion Diagnosis

Development of Technology

Personalized medicine Ex: Pertuzumab

Ex: Biomarker ‘One size fits all’ Strategy Ex: Paclitaxel

28

INTEGRITY BIOMARKER “ROLES” • Disease/Toxicity Profiling • Risk Factor • Screening • Diagnosis (Differential diagnosis) • Staging • Prognosis • Monitoring Disease Progress

• Detection of Recurrence • Predicting Treatment Efficacy / Toxicity • Monitoring Treatment Efficacy / Toxicity • Prediction of Drug Resistance • Selection for Therapy 29

Biomarkers Module • A manually indexed database of biomarker information from diverse sources, fully integrity in Integrity

• The only database that supports biomarker research across the entire profile of a disease:  Proof-of mechanism; safety/treatment monitoring; risk detection and outcomes measurement

30

Biomarker Module • Allows you to see at-a-glance how well-established a specific biomarker use is:  Make more informed decisions around your marker research with greater confidence

• Validity  Emerging  Experimental  Early studies in humans

 Late studies in human  Recommended/approved

31

Biomarker module Biomarker Record

Biomarker Uses

Related information 32

Thanks you! Jenna OH Any Question?

Solution Consultant Life Sciences, Thomson Reuters +82-2-20768128

[email protected] Cheng-Chih Eric Huang Sales Manager, Taiwan Life Sciences, Thomson Reuters + 886-2-25994880 [email protected]

33